Title:
|
UARK 2003-18: A Phase II Study of KIR-ligand Mismatched Natural Killer Cells Transfused before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma
|
| Sponsor: |
University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy
|
| PI: |
Frits van Rhee, M.D., Ph.D.
|
| Phase: |
II
|
| Purpose: |
This study is designed to evaluate the ability of natural killer cells to kill myeloma cells.
|
| Eligibility: |
Approximately 64 patients, male or female, age 18 and older, regardless of race or ethnicity, will participate in this study which is conducted at UAMS only. You are being asked to take part in this study because you have multiple myeloma and have received prior chemotherapy. Additionally, your physician feels that it may be reasonable for you to participate in this study of a new treatment for multiple myeloma.
|
| Treatment: |
The natural killer cells will be given in addition to a standard autologous peripheral blood stem cell transplant (transplant using your stem cells). Natural killer cells are a special type of white blood cells which have the ability to kill myeloma cells. The natural killer cells you will receive will be collected from a carefully chosen family member. An autologous transplant is a procedure in which you are given high dose chemotherapy followed by your own previously collected blood cells which are thawed and transplanted (transfused) into your vein.
|
| Contact: |
|
